In-Hospital Initiation of Cardiovascular Protective Medications for Patients Undergoing Percutaneous Coronary Intervention: Taking Advantage of the Teachable Moment

Journal of Invasive Cardiology

Volumn 15, Issue 11, 2003, Pages 646-652

  Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lipids; Mortality; Outcomes; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; INTERVENTIONAL RADIOLOGY; META ANALYSIS; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; STENTS; TREATMENT OUTCOME;

EID: 0242493591     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. American Heart Association: 2003 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2002.
2. Smith SCJ, Blair SN, Bono RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001;104:1577-1579.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002;106:1893-1900.
4. Adult Treatment Panel III: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001;285:2486-2497.
5. Yusuf S, Peto R, Lewis J, et al. Beta-blocker during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
6. Khalil ME, Basher AW, Btown EJ Jr., Alhaddad IA. A remarkable medical story: Benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol 2001;37:1757-1764.
7. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of betablockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-629.
8. Fonarow GC, French WJ, Parsons LS, et al., for the National Registry of Myocardial infarction 3 Participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial infarction 3. Circulation 2001;103:38-44.
9. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307.
10. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
11. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the rreatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: The National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056-2063.
12. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Program. Eur Heart J 2001;22:554-572.
13. Adult Treatment Panel II: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and rreatmenr of high blood cholesterol in adults. JAMA 1993;269:3015-3023.
14. Fonarow GC. Statin therapy after acute myocardial infarction: Are we adequately treating high risk patients? Curr Athero Report 2002;4:99-106.
15. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
16. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346.
17. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo controlled trial. Lancet 2002;360:7-22.
18. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-3222.
19. Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvasratin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001;285:1711-1718.
20. Thompson PL, Amerena J, Campbell TJ, et al., on behalf of the PACT Investigators. Presented at the World Congress of Cardiology. Sydney, Australia: May 2002.
21. Chan AW, Quinn MJ, Bhatt DL, et al. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:669-675.
22. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
23. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
24. Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol 2000;85:10A-17A.
25. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001;357:1063-1068.
26. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696.
27. Pearson TA, Peters TD, Feury D, et al. The American College of Cardiology Evaluation of Preventative Therapeutics (ACCEPT) Study: Attainment of goals for comprehensive risk reduction in patients with coronary disease in the U.S. J Am Coll Cardiol 1998;31:186A.
28. Burler J, Arbogast PG, BeLue R, et al. Outpatient adherence to bera-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002;40:1589-1595.
29. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:957-1047.
30. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-467.
31. Fonarow GC, Ballanryne CM. In-hospital initiation of lipid lowering therapy for patients with coronary heart disease: The time is now. Circulation 2001;103:2768-2770.
32. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol 2001;87:819-822.
33. Fonarow GC, Gawlinski A, Watson KA, Moughrabi S. Sustained improvement in the treatment of cardiovascular hospitalization atherosclerosis management program: CHAMP. Circulation 2001;104:11-711.
34. Cannon CP, McCabe CH, Bentley J, et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI-16. J Am Coll Cardiol 2001;35:334A.
35. Pearson RR, Horne BD, Maycock CA, et al. An institutional discharge medication program reduces future cardiovascular readmissions and mortality: An analysis of 43,841 patients with coronary artery disease. J Am Coll Cardiol 2002;39:452A.
36. McCarthy M. U.S. heart guidelines program makes a promising start. Lancet 2001;358:1618.
37. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA 2002;287:1269-1276.
38. Debusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120:721-729.